Kronos Bio, Inc.

NasdaqCM:KRON 株式レポート

時価総額：US$52.9m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Kronos Bio マネジメント

マネジメント 基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Deb Knobelman

最高経営責任者

US$723.7k

報酬総額

CEO給与比率38.83%
CEO在任期間1yr
CEOの所有権0.2%
経営陣の平均在職期間データなし
取締役会の平均在任期間6yrs

経営陣の近況

分析記事 • Jun 20

Shareholders Will Probably Hold Off On Increasing Kronos Bio, Inc.'s (NASDAQ:KRON) CEO Compensation For The Time Being

Key Insights Kronos Bio to hold its Annual General Meeting on 25th of June CEO Norbert Bischofberger's total...

Recent updates

分析記事 • Jun 20

Shareholders Will Probably Hold Off On Increasing Kronos Bio, Inc.'s (NASDAQ:KRON) CEO Compensation For The Time Being

Key Insights Kronos Bio to hold its Annual General Meeting on 25th of June CEO Norbert Bischofberger's total...
分析記事 • Jun 11

Is Kronos Bio (NASDAQ:KRON) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Jun 05

Kronos Bio: Still Promising But Riskier Following ASCO Update

Summary Updated data from the ongoing ph2 study of KB-0742 were disappointing, with only a single partial response. Although adverse effects are "manageable" the safety profile is far from ideal. Nevertheless, a high and durable disease control rate was reported in heavily pre-treated patients. Furthermore, MYC-dependent solid tumors (the focus of the next cohorts and the larger target market) were underrepresented. Additionally, there is convincing pharmacokinetic/pharmacodynamic rationale suggesting that better efficacy should be expected from the 80mg 4 days on/ 3 days off cohort. KRON has re-iterated a cash runway into 2H 2026, i.e., beyond major catalysts (KB-0742 readout in 1H 2025, news on Genentech collaboration by mid-2025, and likely first data from KB-0742). Read the full article on Seeking Alpha
Seeking Alpha • May 06

Kronos Bio: Underestimated Drug Discovery Platform

Summary Kronos Bio, Inc.'s drug discovery platform has a lot of potential in targeting transcription regulatory networks. Genetech collaboration validates big pharma interest. KB-0742, Kronos Bio's lead asset, is an orally bioavailable highly selective CDK9 inhibitor that has demonstrated promising single-agent antitumor activity and tolerability in an ongoing ph1/2 study. Kronos Bio will present an update in ASCO (01 June 2024). Top-line results are expected in 1H 2025. KB-9558, Kronos Bio's second internally developed asset, has demonstrated promising preclinical activity against multiple myeloma. Kronos plans initiation of a first-in-human trial in 1H 2025. Read the full article on Seeking Alpha
分析記事 • Jan 19

Is Kronos Bio (NASDAQ:KRON) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
分析記事 • Aug 21

We're Keeping An Eye On Kronos Bio's (NASDAQ:KRON) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Feb 22

We Think Kronos Bio (NASDAQ:KRON) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although...
分析記事 • Nov 01

Is Kronos Bio (NASDAQ:KRON) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Aug 16

Kronos Bio, Invivoscribe to develop companion diagnostic for leukemia drug entospletinib

Kronos Bio (NASDAQ:KRON) and Invivoscribe, a global provider of oncology diagnostic kits and services, on Tuesday said they had inked a deal to develop a companion diagnostic for use with investigational therapy entospletinib. KRON's entospletinib is the company's lead clinical compound. It is currently being evaluated in a phase 3 trial for the treatment of newly diagnosed NPM1-mutated acute myeloid leukemia (AML). KRON said the diagnostic would screen for the NPM1 mutation, which is present in about one-third of all AML patients. KRON stock earlier closed -6% at $4.85.
分析記事 • Jul 07

Is Kronos Bio (NASDAQ:KRON) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
分析記事 • Feb 01

We're Hopeful That Kronos Bio (NASDAQ:KRON) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
分析記事 • Mar 03

How Much Of Kronos Bio, Inc. (NASDAQ:KRON) Do Insiders Own?

If you want to know who really controls Kronos Bio, Inc. ( NASDAQ:KRON ), then you'll have to look at the makeup of its...
分析記事 • Jan 09

Read This Before Selling Kronos Bio, Inc. (NASDAQ:KRON) Shares

It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...

CEO報酬分析

Kronos Bio の収益と比較して、Deb Knobelman の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2025n/an/a

-US$64m

Dec 31 2024US$724kUS$281k

-US$86m

報酬と市場: Debの 総報酬 ($USD 723.71K ) は、 US市場 ($USD 638.05K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Debの報酬と会社の業績を比較するにはデータが不十分です。

CEO

Deb Knobelman (51 yo)

1yr
在職期間
US$723,705
報酬

Dr. Deborah A. Knobelman, also known as Deb, Ph. D. has been Interim CEO and President of Kronos Bio, Inc. since December 3, 2024 and serves as its Chief Financial Officer since June 03, 2024. She has been...

取締役

名称ポジション在職期間報酬所有権
Joshua Kazam
Co-Founder & Director8yrsUS$62.64k0.60%
$ 317.8k
David Tanen
Secretary & Director8yrsUS$84.64k1.5%
$ 792.3k
Norbert Bischofberger
Director7.2yrsUS$2.33m21.15%
$ 11.2m
Owen Witte
Scientific Advisory Board Chairmanno dataデータなしデータなし
Arie Belldegrun
Independent Chairman of the Board7.6yrsUS$131.84k1.11%
$ 589.3k
Elena Ridloff
Independent Director4.8yrsUS$77.03k0.023%
$ 12.1k
Taiyin Yang
Independent Director4.3yrsUS$78.14k0.019%
$ 9.8k
Roshawn Blunt
Independent Director3.6yrsUS$68.27k0%
$ 0
Angela Koehler
Scientific Advisory Board Memberno dataデータなしデータなし
Robert Eisenman
Scientific Advisory Board Memberno dataデータなしデータなし
Myles Brown
Scientific Advisory Board Memberno dataデータなしデータなし
Katherine Stultz
Independent Director2.3yrsUS$106.12k0%
$ 0
6.0yrs
平均在職期間
54yo
平均年齢

経験豊富なボード: KRONの 取締役会 は 経験豊富 であると考えられます ( 6年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2025/06/20 21:55
終値2025/06/20 00:00
収益2025/03/31
年間収益2024/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Kronos Bio, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3

アナリスト機関
Zhiqiang ShuBerenberg
Robert BurnsH.C. Wainwright & Co.
Michael YeeJefferies LLC